Piper Jaffray has published a research report on Illumina ILMN after Roche announced a $44.50/share tender offer to acquire the company last night.
In the report, Piper Jaffray writes, "Roche announced a tender offer to acquire Illumina for $44.50 or ~$5.7B on a fully diluted basis, representing an 18.2% premium to yesterday's closing price. We view the Roche/Illumina combination as a strategic fit, with Illumina benefiting from Roche's diagnostic presence and broad distribution and Roche gaining access to the market leading next-generation sequencing business. Illumina's board has rejected Roche's overtures and we suspect an offer greater than $44.50 (at least 25% higher or ~$56) will be necessary to seal the deal, resulting in a potentially drawn out process (similar to Roche's acquisition of Ventana)."
Piper Jaffray maintains its Neutral rating on Illumina, which closed yesterday at $37.69.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in